Investor Type | Firm |
Industries | BioTech • FinTech (& Financials services) • HealthTech (& Fitness) • Medical Devices (& Hospital Services) • Healthcare (& Wellness) • Consumer • Pharmaceutical (& Medicine) |
Stages | Seed, Series A |
Investing | United States • China |
Investment Range | $100,000 - $5,000,000 |
Investment Sweet Spot | $1,500,000 |
Assets Under Management | $188,000,000 |
BVCF, or Bioveda China Fund, is a specialist investment firm with a focus on the burgeoning sectors of BioTech, FinTech, HealthTech, Medical Devices, Healthcare, Consumer goods, and Pharmaceuticals. They have a strong presence in these industries, leveraging their expertise in areas where technology and life sciences converge. The fund has established a niche in providing capital to innovative companies within these domains. With a defined investment range, their minimum investment starts at $100,000, going up to a maximum of $5,000,000, while their sweet spot lies at $1,500,000, indicating the typical scale of investment BVCF aims to place in their portfolio companies. They specialize in the early stages of a company's lifecycle, particularly Seed and Series A funding rounds, working closely with entrepreneurs and start-up teams to scale their organizations effectively. The fund manages assets totaling $188,000,000, signifying a robust pool of resources dedicated to fostering growth and innovation within their target industries. Their investment thesis revolves around identifying and nurturing high-potential companies that are poised to make significant impacts in their respective fields, particularly within the dynamic and rapidly growing Chinese market. BVCF's team, listed on their website, comprises industry professionals with varied expertise, positioned to provide portfolio companies with guidance, resources, and support to ensure their success and develop breakthroughs in their industries.